

## Supplementary File

### CONSORT 2010 Checklist

| Section                   | Item # | Item Description  | Location in Manuscript                       |
|---------------------------|--------|---|--|
| <b>Title and Abstract</b> |        |   |  |
|                           | 1a     | Identification as a randomized trial in the title   | Title  |
|                           | 1b     | Structured summary including trial design, methods, results, and conclusions (for abstract) | Abstract                                     |
| <b>Introduction</b>       |        |   |  |
|                           | 2a     | Scientific background and explanation of rationale  | Introduction, paragraphs 1–2                 |
|                           | 2b     | Specific objectives or hypotheses   | Introduction, final paragraph                |
| <b>Methods</b>            |        |   |  |
| <b>Trial design</b>       |        |   |  |
|                           | 3a     | Description of trial design (e.g., parallel, cluster)                                       | Method, Study Design                         |
|                           | 3b     | Important changes to methods after trial commencement (if any)                              | Not applicable                               |
| <b>Participants</b>       |        |   |  |
|                           | 4a     | Eligibility criteria for participants   | Method, Participants                         |
|                           | 4b     | Settings and locations where the data were collected  | Method, Study Design and Setting             |
| <b>Interventions</b>      |        |   |  |
|                           | 5      | Precisely describe the interventions for each group   | Method, Intervention                         |
| <b>Outcomes</b>           |        |   |  |
|                           | 6a     | Completely defined pre-specified primary and secondary outcome measures                     | Method, Outcome Measures                     |
|                           | 6b     | Changes to trial outcomes after the trial commenced (if any)                                | Not applicable                               |
| <b>Sample size</b>        |        |   |  |
|                           | 7a     | How sample size was determined  | Method, Sample Size and Statistical Analysis |

|                            |      |  |  |
|----------------------------|------|--|--|
|                            | 7b   | Explanation of any interim analyses and stopping guidelines                              | Not applicable   |
| <b>Randomization</b>       |      |  |  |
|                            | 8a   | Method used to generate the random allocation sequence                                   | Method, Randomization and Blinding                               |
|                            | 8b   | Type of randomization (e.g., block, stratified)  | Method, Randomization and Blinding                               |
|                            | 9    | Mechanism used to implement the random allocation sequence (e.g., sealed envelopes)      | Method, Randomization and Blinding                               |
|                            | 10   | Who generated the allocation sequence, enrolled participants, and assigned interventions | Method, Randomization and Blinding                               |
| <b>Blinding</b>            |      |  |  |
|                            | 11 a | If done, who was blinded after assignment to interventions                               | Method, Randomization and Blinding                               |
|                            | 11 b | If relevant, description of the similarity of interventions                              | Not applicable (psychosocial interventions inherently different) |
| <b>Statistical methods</b> |      |  |  |
|                            | 12 a | Statistical methods used to compare groups for primary and secondary outcomes            | Method, Sample Size and Statistical Analysis                     |
|                            | 12 b | Methods for additional analyses (e.g., subgroup, adjusted analyses)                      | Method, Sample Size and Statistical Analysis                     |
| <b>Results</b>             |      |  |  |
| <b>Participant flow</b>    |      |  |  |
|                            | 13 a | Number of participants randomly assigned, received intended treatment, and analyzed      | Results, Participants; Figure 1 (CONSORT Flowchart)              |
|                            | 13 b | Losses and exclusions after randomization (with reasons)                                 | Results, Participants  |
| <b>Recruitment</b>         |      |  |  |
|                            | 14 a | Dates defining the periods of recruitment and follow-up                                  | Method, Study Design and Setting                                 |
|                            | 14 b | Why the trial ended or was stopped   | Not applicable   |
| <b>Baseline data</b>       |      |  |  |

|                                |         |  |   |
|--------------------------------|---------|--|---|
|                                | 15      | Baseline demographic and clinical characteristics of each group                | Table 1   |
| <b>Numbers analyzed</b>        |         |  |   |
|                                | 16      | Number of participants analyzed in each group                                  | Results, Tables 2–5                               |
| <b>Outcomes and estimation</b> |         |  |   |
|                                | 17<br>a | Results for each primary and secondary outcome                                 | Results, Tables 2–5                               |
|                                | 17<br>b | Estimated effect size and precision (e.g., 95% CI)                             | Results, Tables 2–3 (Cohen's <i>*d*</i> reported) |
| <b>Ancillary analyses</b>      |         |  |   |
|                                | 18      | Results of other analyses (e.g., subgroup, adjusted)                           | Results, Table 5 (post-hoc Friedman)              |
| <b>Discussion</b>              |         |  |   |
| <b>Limitations</b>             |         |  |   |
|                                | 19      | Limitations of the study, addressing sources of potential bias and imprecision | Discussion, Limitations and Strengths             |
| <b>Generalizability</b>        |         |  |   |
|                                | 20      | Generalizability (external validity) of the trial findings                     | Discussion, Implications for Practice             |
| <b>Interpretation</b>          |         |  |   |
|                                | 21      | Interpretation consistent with results, balancing benefits and harms           | Discussion, Conclusion                            |
| <b>Other Informations</b>      |         |  |   |
| <b>Registration</b>            |         |  |   |
|                                | 23      | Registration number and name of trial registry                                 | Method, Study Design and Setting                  |
| <b>Protocol</b>                |         |  |   |
|                                | 24      | Where the full trial protocol can be accessed (if available)                   | Available from corresponding author upon request  |
| <b>Funding</b>                 |         |  |   |
|                                | 25      | Sources of funding and role of funders   | Method, Study Design and Setting                  |